ICMC: Initiative for Certification of Manufacturing Capabilities
Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
October 07, 2024 07:58 ET | Dark Horse Consulting Group
Dark Horse Consulting Group, leading cell and gene therapy consultancy, today unveils the Initiative for Certification of Manufacturing Capabilities: ICMC™
The Dark Horse Consulting Group logo contains the initials DHC, rendered in British Racing Green and with a profile of a horse's head within the "D"
Dark Horse Consulting Group Acquires BioTechLogic, Inc.
October 03, 2024 11:18 ET | Dark Horse Consulting Group
Dark Horse Consulting Group, the global leader in cell and gene therapy consulting, is delighted to announce the acquisition of BioTechLogic, Inc.
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
June 20, 2024 08:45 ET | ClearPoint Neuro, Inc.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 08:00 ET | Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 07:00 ET | BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
SentiBioLogo.jpg
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
January 05, 2024 16:05 ET | Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
2018_DHC_logo_Color_Large.jpg
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
November 13, 2023 16:20 ET | Dark Horse Consulting Group
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
October 11, 2023 06:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
September 05, 2023 08:30 ET | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
SentiBioLogo.jpg
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
August 11, 2023 08:35 ET | Senti Biosciences, Inc.
– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on...